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Abstract
Background: Respiratory syncytial virus (RSV) is a major cause of viral bronchiolitis in infants
worldwide, and environmental, viral and host factors are all of importance for disease susceptibility
and severity. To study the systemic host response to this disease we used the microarray
technology to measure mRNA gene expression levels in whole blood of five male infants
hospitalised with acute RSV, subtype B, bronchiolitis versus five one year old male controls
exposed to RSV during infancy without bronchiolitis. The gene expression levels were further
evaluated in a new experiment using quantitative real-time polymerase chain reaction (QRT-PCR)
both in the five infants selected for microarray and in 13 other infants hospitalised with the same
disease.
Results:  Among the 30 genes most differentially expressed by microarray nearly 50% were
involved in immunological processes. We found the highly upregulated interferon, alpha-inducible
protein 27 (IFI27) and the highly downregulated gene Charcot-Leyden crystal protein (CLC) to be
the two most differentially expressed genes in the microarray study. When performing QRT-PCR
on these genes IFI27 was upregulated in all but one infant, and CLC was downregulated in all 18
infants, and similar to that given by microarray.
Conclusion: The gene IFI27 is upregulated and the gene CLC is downregulated in whole blood of
infants hospitalised with RSV, subtype B, bronchiolitis and is not reported before. More studies are
needed to elucidate the specificity of these gene expressions in association with host response to
this virus in bronchiolitis of moderate severity.
Text
Why some infants develop bronchiolitis when exposed to
respiratory syncytial virus (RSV) is poorly understood,
and several aspects of environmental and host immunity
have been extensively studied [1,2]. The role of the virus
itself in modulating host immune response has also been
investigated. Recent studies have revealed an important
role of certain RSV surface proteins to counteract the host
interferon (IFN) response, a response known to be impor-
tant for viral clearance [3,4].
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Microarray can detect the simultaneous expressions and
interactions of thousands of genes [5]. This technology
was used as a hypothesis generating tool to identify the
most differentially expressed genes in whole blood of five
male infants hospitalised with RSV, subtype B, bronchioli-
tis versus five one year old male controls exposed to RSV
during infancy without being hospitalized and/or treated
for acute bronchiolitis. To further validate our results
quantitative real-time polymerase chain reaction (QRT-
PCR) was performed on the most differentially expressed
genes given by the microarray experiment both in the
infants selected for microarray and in a new population of
13 more infants admitted to our hospital with the same
disease [6]. Four of the five one year old male controls
were used as a pooled exogenous control in the QRT-PCR
study.
The infants were diagnosed with bronchiolitis if having
symptoms from the lower airways characterized by
wheezing, dyspnea, respiratory distress, poor feeding,
tachypnea and fine crepitations upon auscultation when
examined by the doctor on call in the emergency room
[7]. The doctor also conducted a structured clinical inter-
view with the parents and NPA was taken for viral analysis
with multiplex RT-PCR [8]. Median duration of symp-
toms prior to hospitalisation was 4 (range 2–7) days,
median age at admission was 3 (range 1–8) months and
median duration of hospitalisation was 3 (range 1–8)
days. Severity of illness was comparable in all 18 infants,
except for one infant who had a prolonged hospitalisation
period of 8 days. However, all infants received the same
routine treatment including inhalations with nebulised
racemic epinephrine and none of the infants needed arti-
ficial ventilation. More information on the selection of
cases and controls is described elsewhere [See Additional
file 1].
Microarray results
The Feature Extraction software identified 19663 unique
gene sequences. After normalization and filtering of con-
trol spots and spots with signal intensities below 300 in
either channel a total of 15761 genes were available for
further evaluation. When performing statistical analysis of
the data using the BAMarray software we found 439 genes
to be significantly differentially expressed between cases
and controls. Furthermore, by also analyzing the same
data with the Rosetta Luminator software, a list of 1544
genes with P value ≤ 0.01 was identified. 54 of these genes
had mean fold changes of at least ± 2.50. Finally, by com-
paring the list of 439 genes found by BAMarray with the
list of 54 genes identified with the Rosetta Luminator soft-
ware, a total of 30 genes occurred in both lists and were
selected for final presentation (tab 1). More methodolog-
ical details are described elsewhere [See Additional file 1].
22 of these 30 genes were upregulated while 8 genes were
downregulated, and 13 of the 30 genes were involved in
several aspects of immune response. Among these were
the upregulated interferon inducible genes IFI27, IFI44,
EIF2AK2, IFI44L, OAS3 and G1P2 and the downregulated
genes HLA-DRB4, HLA-DQA1 and CLC (tab 1).
QRT-PCR results
A QRT-PCR study with TaqMan Low Density Array
(TLDA) cards was performed on 23 of the most differen-
tially expressed genes given by microarray to compare the
two methods before the study was applied on a new
patient population. Six genes failed amplification and
were excluded from further analyses. More methodologi-
cal details are described elsewhere [See Additional file 1].
Five of the 17 genes available for further evaluation
(DNAPTP6, HP, IFI27, MS4A4A and STXBP2) were upreg-
ulated and one gene (CLC) was downregulated in all five
male infants when compared to the pooled exogenous
control. Seven genes (BPGM, G1P2, HBD, IFI44L,
MARCO, MMP9 and NQO2) were upregulated in all but
one infant while four genes (EPSTI1, ERAF, HBE1 and
IFI44) were upregulated in all but two infants (fig 1).
When comparing the gene expression results of the TLDA
study and the microarray experiment for each of the five
infants the expression profiles were quite similar for the
genes CLC, DNAPTP6, IFI27 and MS4A4A. The remaining
genes showed more variations (fig 1).
To evaluate the impact of the 17 genes expressed by
microarray a new cohort was tested using QRT-PCR. In the
new cohort of 13 infants hospitalised with the same dis-
ease 11 of the 17 genes were significantly differentially
expressed in accordance with the results from the micro-
array study (p < 0.01; independent samples t-test). In
order to see if some of the genes associated with immuno-
logical processes could also be differentially expressed in
the new cohort, as well as in the five infants selected for
microarray, we evaluated the expressions of the six
immune response genes available for studies with TLDA
cards. The gene IFI27 was upregulated in 17 infants and
slightly downregulated in one infant while the gene IFI44
was downregulated in 15 infants and upregulated in three
infants. The genes IFI44L and MARCO were downregu-
lated in 14 infants and upregulated in four infants, and
the gene G1P2 was downregulated and upregulated in
nine infants, respectively. Finally, the gene CLC was
downregulated in all 18 infants (fig 2).
Discussion
The aim of the present study was to use microarray as a
hypothesis generating tool to identify the most differen-
tially expressed genes in whole blood of infants hospital-
ised with RSV, subtype B, bronchiolitis, and to furtherBMC Infectious Diseases 2006, 6:175 http://www.biomedcentral.com/1471-2334/6/175
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Table 1: Significant genes with mean fold changes1 of at least ± 2.50 as given by microarray2
GeneBank identifier Gene symbol Gene name Biological process Fold change
NM_005532 IFI27 Interferon, alpha-inducible protein 27 Immune response +13.29
NM_005143 HP Haptoglobin Defence response +5.71
NM_006417 IFI44 Interferon-induced protein 44 Immune response +4.86
NM_024021 MS4A4A Membrane-spanning 4-domains, subfamily A, member 4 Signal transduction +4.42
NM_004994 MMP9 Matrix metalloproteinase 9 Collagen catabolism +3.93
BC035682 HBZ Hemoglobin, zeta Oxygen transport +3.78
NM_015535 DNAPTP6 DNA polymerase-transactivated protein 6 +3.57
NM_000519 HBD Hemoglobin, delta Oxygen transport +3.40
NM_005330 HBE1 Hemoglobin, epsilon 1 Oxygen transport +3.06
NM_006187 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Immune response +2.99
NM_000566 FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) Immune response +2.88
NM_006949 STXBP2 Syntaxin binding protein 2 Intracellular protein transport +2.86
NM_033255 EPSTI1 Epithelial stromal interaction 1 (breast) +2.83
NM_002759 EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 Immune response +2.78
NM_016633 ERAF Erythroid associated factor Hemoglobin metabolism +2.73
NM_006770 MARCO Macrophage receptor with collagenous structure Response to pathogenic bacteria +2.72
NM_001724 BPGM 2,3-bisphosphoglycerate mutase Carbohydrate metabolism +2.60
NM_000904 NQO2 NAD(P)H dehydrogenase, quinone 2 Electron transport +2.56
NM_006820 IFI44L Interferon-induced protein 44-like Immune response +2.55
NM_005101 G1P2 Interferon, alpha-inducible protein (clone IFI-15K) Immune response +2.54
NM_024572 GALNT14 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14
+2.53
NM_203339 CLU Clusterin Immune response +2.50
NM_005581 LU Lutheran blood group (Auberger b antigen included) Cell adhesion -2.55
NM_080819 GPR78 G protein-coupled receptor 78 G-protein coupled receptor 
protein signaling pathway
-2.70
NM_000797 DRD4 Dopamine receptor D4 G-protein coupled receptor 
protein signaling pathway
-2.89
NM_006249 PRB3 Proline-rich protein BstNI subfamily 3 G-protein coupled receptor 
protein signaling pathway
-2.91
NM_021983 HLA-DRB4 Homo sapiens major histocompatibility complex, class II, 
DR beta 4
Immune response -3.31
NM_000558 HBA1 Hemoglobin alpha 1 Oxygen transport -4.61
L34088 HLA-DQA1 Major histocompatibility complex, class II, DQ alpha 1 Immune response -4.70
NM_001828 CLC Charcot-Leyden crystal protein Antimicrobial humoral response -6.08
1Gene expressions given as mean of the individual fold changes (signal intensity in a case minus signal intensity in the corresponding control). 2Gene 
expressions as given by microarray in whole blood of five male infants hospitalised with respiratory syncytial virus, subtype B, bronchiolitis versus 
five one year old male controls exposed to RSV during infancy but not hospitalised and/or treated for bronchiolitisBMC Infectious Diseases 2006, 6:175 http://www.biomedcentral.com/1471-2334/6/175
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Evaluation of genes differentially expressed by microarray (blue bars) with QRT-PCR (red bars) Figure 1
Evaluation of genes differentially expressed by microarray (blue bars) with QRT-PCR (red bars). The microarray 
experiment was conducted as a case-control study with whole blood gene expressions given as ratio of signal intensity in each 
of five male infants hospitalised with respiratory syncytial virus, subtype B, bronchiolitis versus signal intensity in a correspond-
ing one year old male control exposed to the virus during infancy but not hospitalised and/or treated for bronchiolitis. The 
quantitative real-time polymerase chain reaction (QRT-PCR) study used TaqMan Low Density Array (TLDA) cards with gene 
expression given as mean relative quantification (RQ) from triplets of each gene and analyzed in the same five male infants as 
selected for microarray. A pooled sample from four of the five one year old male controls was used as exogenous control and 
beta-glucuronidase (GUSB) was used as endogenous control in the QRT-PCR study. The following genes (gene symbol and 
name) were evaluated; BPGM: 2,3-bisphosphoglycerate mutase, CLC: Charcot-Leyden crystal protein, DNAPTP6: DNA 
polymerase-transactivated protein 6, EPSTI1: Epithelial stromal interaction 1 (breast), ERAF: Erythroid associated factor, G1P2: 
Interferon, alpha-inducible protein (clone IFI-15K), HBD: Hemoglobin, delta, HBE1: Hemoglobin, epsilon 1, HP: Haptoglobin, 
IFI27: Interferon, alpha-inducible protein 27, IFI44: Interferon-induced protein 44, IFI44L: Interferon-induced protein 44-like, 
MARCO: Macrophage receptor with collagenous structure, MMP9: Matrix metalloproteinase 9, MS4A4A: Membrane-spanning 
4-domains, subfamily A, member 4, NQO2: NAD(P)H dehydrogenase, quinone 2, STXBP2: Syntaxin binding protein 2
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evaluate some of these genes with QRT-PCR. We found
the interferon, alpha-inducible protein 27 (IFI27) and
Charcot-Leyden crystal protein (CLC) to be the most dif-
ferentially expressed genes in this study and not to be
reported before in conjunction with acute viral bronchi-
olitis.
All 18 hospitalised infants in our study suffered from
acute bronchiolitis of moderate severity. They were hospi-
talised because of severe respiratory difficulties, but were
not in need of assisted ventilation including treatment
with continuous positive airway pressure (CPAP) or
mechanical ventilation. Our population is therefore rep-
resentative for the majority of cases hospitalised during
infancy worldwide [9]. The children in the control group
were all healthy one year old children at the time of clini-
cal examination and blood collection. They were repre-
senting the majority of infants undergoing RSV infection
with only mild symptoms. This group was chosen to
exclude children from the control group that could have a
possible genomic predisposition for a more abnormal
immune response, characterizing the infants with overt
bronchiolitis. We would also be interested in differentiat-
ing between the gene expression profile of mild cases and
severe cases of RSV infection, but this will require a new
study and a design specific to support this question. The
gene expression profile found in the present study is the
result of RSV infection. It would in further studies be inter-
esting to examine if other respiratory viral infections caus-
ing bronchiolitis give a similar or different expression
pattern.
One limitation of the present study is the discrepancy in
age between the cases and controls. It is well known that
the immunological responses mature very rapidly from
birth to age one year and the differences observed may
therefore simply be due to age rather than to any infection
related host response [10]. In order to confirm our gene
expression results new studies, which also include a con-
trol group being more closely age matched, are very much
needed. This study is also rather small, consisting of only
18 infants, and warrants us to be cautious to the interpre-
tations of the results given.
The immune response to RSV infection, as with any other
infection is comprised of an innate response, and subse-
quently by activation of humoral and cellular specific
immunity. The cellular immune response seems to be
important in controlling the infection once initiated and
for clearance of the virus, while the humoral immune
response is important in providing protection against sub-
sequent infection [11]. The interferons (IFNs) are a
diverse family of cytokines consisting in humans mainly
of IFN-alpha and IFN-beta (type I) and IFN-gamma (type
II). Both types play an essential role in host immunity by
inhibiting the replication and spread of viral, bacterial,
and parasitic pathogens. Several studies have shown the
importance of IFN-gamma as regulators of host response
to RSV infection [12,13]. However, the sensitivity of RSV
to the antiviral activity of INF-alpha is known to be low,
at least when compared with that of other viruses [14].
IFNs mediate their effects via transcription of interferon
stimulated genes (ISGs) by binding to cell surface recep-
tors activating members of the JAK-STAT pathway [15].
Studies have shown an important role of the RSV surface
protein NS1 to antagonize the type I IFN-mediated antivi-
ral response [16]. Also, recent in vitro studies have shown
that knocking out the NS1 gene results in upregulation of
several ISGs, increased viral clearance and modulation of
the host response towards a Th1 phenotype [3,4,17]. The
gene IFI27 belong to a group of small ISGs [18,19]. Its
biological functions have yet to be revealed, but studies
have found this gene to be highly upregulated during can-
cer development in several tissues and in children with
untreated juvenile dermatomyositis [20]. It has also been
QRT-PCR study of six whole blood immune response genes  as given by microarray Figure 2
QRT-PCR study of six whole blood immune response 
genes as given by microarray. A quantitative real-time 
polymerase chain reaction (QRT-PCR) study using TaqMan 
Low Density Array (TLDA) cards was performed with gene 
expressions given as mean relative quantification (RQ) from 
triplets of each gene. Analyzed in 18 infants hospitalised with 
respiratory syncytial virus, subtype B, bronchiolitis versus a 
pooled sample from four one year old male children exposed 
to RSV during infancy but not treated and/or hospitalised for 
bronchiolitis during infancy as exogenous control and with 
beta-glucuronidase (GUSB) as endogenous control. The fol-
lowing genes (gene symbol and name) were studied; CLC: 
Charcot-Leyden crystal protein, G1P2: Interferon, alpha-
inducible protein (clone IFI-15K), IFI27: Interferon, alpha-
inducible protein 27, IFI44: Interferon-induced protein 44, 
IFI44L: Interferon-induced protein 44-like, MARCO:Macro-
phage receptor with collagenous structure
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shown to have a direct antiviral effect against certain
viruses [21]. In our study IFI27 was highly upregulated in
all but one infant even after evaluation with QRT-PCR.
However, the specific biological role(s) of this gene, if
any, in early-life RSV bronchiolitis need more studies.
Major basic protein (MBP), eosinophil peroxidase (EPO),
eosinophil cationic protein (ECP), eosinophil-derived
neurotoxin (EDN) and Charcot-Leyden crystal (CLC) pro-
tein are major secretory effector proteins of eosinophils
[22]. Eosinophilia of blood and tissue is classically associ-
ated with parasitic and especially invasive helminthic
infections and is not typical for either bacterial or viral
infections. However, several groups have shown evidence
of eosinophil degranulation in the lung parenchyma dur-
ing RSV infection, and both ECP and EDN are shown to
have antiviral effects against RSV in vitro [23]. Further-
more, in vivo studies of infants with RSV bronchiolitis
have found blood levels of ECP to be higher during con-
valescence than during acute disease and therefore possi-
bly play a role in the development of the long-standing
inflammatory reaction seen in the airways after RSV bron-
chiolitis, and in which eosinophils play an important role
[24,25]. In our study we found the gene coding for the
eosinophil-derived phospholipase CLC to be downregu-
lated in peripheral blood of all infants even after evalua-
tion with QRT-PCR. Studies have shown that eosinophil-
derived phospholipases may contribute to surfactant dys-
function in the asthmatic lung [26]. However, the possi-
ble importance of CLC downregulation in peripheral
blood of infants with RSV bronchiolitis need more stud-
ies.
The present study shows the importance of further evalu-
ation of microarray data with other methods such as QRT-
PCR and protein expression analyses. Microarray and
QRT-PCR are suitable tools for gene expression studies
related to acute RSV bronchiolitis in infants and can
increase our knowledge of the host response to this dis-
ease. The present study identified the genes IFI27 and CLC
to be highly differentially expressed in whole blood of
infants hospitalised with RSV, subtype B, bronchiolitis of
moderate severity. However, more studies are needed to
identify the specificity of these two genes in relation to
this disease.
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